This work describes the production of high-specific activity 55 Co and the evaluation of the stability of Co as a promising new radiotracer for PET imaging of cancer and other diseases.
P OSITRON EMISSION TOMOGRAPHY (PET)
is a common imaging modality in nuclear medicine. Clinical interest in positron-emitting metals has increased due to their longer half-lives, which are more suitable for radiolabeling macromolecules such as antibodies, peptides, and nanoparticles over traditional PET isotopes such as 18 F, 11 C, and 15 O. 1, 2 Currently, the most common radiometals used in PET imaging are 64 Cu, 68 Ga, 89 Zr, and 86 Y, with 64 Cu, 68 Ga, and 89 Zr being used in clinical trials. [3] [4] [5] The chemistry of each metal is different, and chelates need to be optimized for the radiometal of interest that will provide stable metal-chelate complexes in vivo. 55 Co is another isotope of interest for PET imaging. It has a half-life of 17.5 hours, a positron branching ratio of 77%, and an average positron energy of 570 keV, qualities that make it well suited for imaging with peptides, small molecules, and antibodies. 6-11 55 CoCl 2 has previously been used clinically to image ischemia in stroke patients [12] [13] [14] [15] and in late-onset epileptic seizures 16 due to its ability to mimic calcium uptake.
However, it is important to study the preclinical pharmacologic properties of this isotope when it will be incorporated into targeting ligands as imaging agents to probe other diseases. Thus, we investigated the biodistribution of free 55 CoCl 2 along with the stability of 55 Co-chelate-peptide complexes in vivo. 55 Co can be produced via several nuclear reactions, such as 58 Ni(p,) 55 Co, 17-20 56 Fe(p,2n) 55 Co, 21,22 and 54 Fe(d,n) 55 Co. 23, 24 The 54 Fe(d,n) 55 Co has the highest measured cross section at low energies 8, 25 ; however, 54 Fe has a low natural abundance. Thus, this target may be cost prohibitive for routine production in most laboratories. Co. Additionally, the decay scheme for this isotope yields many high-energy photons. The proton reaction on 58 Ni has a higher cross section at lower energies than the proton reaction on 56 Fe, 19, 20, 22 making it more desirable for low-energy (15 MeV) cyclotrons. This method also produces a small amount of an inseparable side product, Ni has previously been reported. 11, 18, 26, 27 The specific activity of 55 
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has been investigated using both ion chromatography of productions using 58 Ni
26
, and 4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) titration of productions using nat Ni. 27 High-effective specific activity (ESA) of radiometals is important, as metal contaminants have negative impacts on radiolabeling. 28, 29 For best radiolabeling results using 55 Co, ESA measurements must be performed and productions optimized so that high-specific activity material can be obtained.
In this work, we discuss the production of 55 Co via the 58 Ni (p,) 55 Co reaction and report its ESA using both DOTA titrations and ion chromatography. 28 We also report the in vivo Co-DO3A-L19K-FDNB were compared at 24 and 48 hours postinjection to establish the in vivo stability of 55 Co chelated with NO2A-and DO3A-peptide conjugates in tumor-bearing mice.
Materials and Methods

Materials
Trace metal grade reagents were purchased from SigmaAldrich (St. Louis, MO) and used without purification, and Milli-Q deionized water (18 M cm
À1
) was used for all dilutions unless stated otherwise. All glassware and vials were acid washed in 8 M HNO 3 for 24 hours prior to use. DOTA was purchased from Macrocyclics (Dallas, TX). Two versions of the peptide L19K were synthesized by CPC Scientific (Sunnyvale, CA) consisting of the sequence DO3A-or NO2A-PEG 4-GGNECDIARMWEWECFERK-CONH 2 , with a Cys-Cys disulfide bridge and polyethylene glycol (PEG) as a spacer between peptide and chelate. 58 Ni was purchased from Isoflex (San Francisco, CA) with 99.48% isotopic enrichment.
Targetry and Irradiation
Forty-five to 55 mg of 58 Ni in powder form was plated onto a gold disk by electrodeposition as previously described by
McCarthy and colleagues and Szelecsenyi and colleagues. 33, 34 The electroplating cell was 9 cm in height, with an inner diameter of 1.8 cm. The bottom of the cell consisted of a Teflon base that connected to the gold disk, exposing a 5 mm circle. A graphite rod was used as the cathode and stirred the solution slowly as a voltage of 2.5 V was applied for 12 hours. The current remained between 8 and 20 mA throughout the process. Targets were irradiated on a 15 MeV cyclotron (CS-15) for 20 to 60 mAhr and were able to withstand currents up to 30 mA. Targets were allowed to sit for 2 hours prior to processing to allow short-lived contaminants to decay.
Purification
For processing, targets were placed in 10 mL of 9 M HCl and heated with reflux for approximately 1 hour to dissolve the nickel from the gold disk. Once the solution cooled, it was placed in a 1 cm Â 10 cm glass column (Bio-Rad, Hercules, CA) with 2.5 g AG1-X8 resin (Bio-Rad). To determine separation conditions, the eluate and 10 to 40 mL of 9 M HCl were collected, followed by another 10 mL of 0.5 M HCl to elute the 55 Co. Fractions of 1 mL were collected and analyzed using a high-purity germanium (HPGe) detector (Canberra, Meriden, CT), and the final 55 Co fractions were evaporated to dryness and reconstituted with 20 mL Milli-Q water. 55 Co productions were analyzed using ion chromatography 28 for transition metal contamination.
Effective Specific Activity
DOTA titrations were performed to determine the ESA of 55 Co productions, and the method was adapted from the The final volume was brought to 50 mL using 0.5 M ammonium acetate buffer pH 5.5. The solutions were placed in an agitating incubator at 37ºC for 30 minutes. Solutions were cooled to room temperature and then centrifuged. A 1 mL aliquot from each DOTA concentration and 1 mL of unbound 55 Co, for use as a control, were spotted separately onto a silica plate for thin-layer chromatography (TLC) using a 1:1 mixture of 10% w/v ammonium acetate and methanol as the eluent. Plates were analyzed using a Radio TLC Plate Reader (Washington, DC) and analyzed for the percent 55 Co incorporated into DOTA. Data were plotted as the molar concentration of DOTA versus percent 55 Co incorporation. The curve was fit using a sigmoid plot fit program in Prism Co that bound to 50% of the DOTA molecules, was determined from this fit. The ESA was calculated as two times the EC 50 value.
Animal Models
All animal care was performed as stated in the Guide for Care and Use for Laboratory Animals by the National Institutes of Health under a protocol approved by the Animal Studies Committee at Washington University in St. Louis. Female athymic Nu/Nu mice (National Cancer Institute, Bethesda, MD) age 6 to 9 weeks were anesthetized with a ketamine/ xylazine cocktail (VEDCO, St, Joseph, MO). One hundred microliters of approximately 2 Â 10 7 cell/mL HCT-116 colon cancer cells suspended in saline was subcutaneously injected into the shoulder. Tumors were allowed to grow for 2 weeks before imaging and biodistribution studies.
Small Animal PET/CT imaging
Prior to imaging, animals were anesthetized with 2% isoflurane. One hundred microliters of 74 kBq/mL 55 CoCl 2 in saline was injected into HCT-116 tumor-bearing mice (n = 4) via tail vein injection and imaged using an Inveon MicroPET/ CT scanner (Siemens, Washington, DC) at 2, 24, and 48 hours postinjection. Static PET images were acquired for 20 minutes. PET data were reconstructed using standard methods with the maximum a posteriori probability (MAP) algorithm and coregistered with computed tomography (CT) using image display software (Inveon Research Workplace Workstation, Siemens). Volumes of interest (VOI) were drawn using CT anatomic guidelines. Co-DO3A-FDNB in saline was injected into HCT-116 tumor-bearing mice. For each agent, three mice were sacrificed at 24 and 48 hours postinjection followed by removal of blood, lung, liver, spleen, kidney, muscle, fat, heart, brain, bone, tumor, stomach, small intestine, upper large intestine, and lower large intestine. Each organ was weighed and measured for radioactivity using a gamma counter. The radioactivity was background subtracted, decay corrected to the time of injection, and reported as percent injected dose/g tissue (% ID/g).
Statistical Analysis
All data were analyzed using Prism version 6 and reported as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used to calculate p values in order to compare more than two groups with one variable, and p values with a 95% confidence interval (< .05) were considered significant.
Results
Production Co activity.
CoCl 2 Small Animal PET/CT Imaging and Biodistribution
As an emerging radioisotope applicable in oncologic PET imaging, very few data existed about the in vivo stability of different 55
Co-chelate complexes. HCT-116 tumor xenografts were imaged ( Figure 3A ) and post-PET biodistribution studies (Table 1) were performed at 2, 24, and 48 hours postinjection to investigate the distribution of free 55 CoCl 2 in this model. Interestingly, free 55 CoCl 2 was observed in the tumor at each of these time points. Tumor to blood ratios at 2 and 48 hours were 0.6 ± 0.1 and 1.9 ± 0.4, respectively (p = .006), exhibiting a threefold increase due to fast blood clearance and relatively slow tumor washout (see Figure 3B and Table 1 ). High uptake in the heart at 2 hours postinjection could be due to the potential of Co 2+ to mimic calcium influx. 12, 15 Clearance of free 55 CoCl 2 occurred through the liver and kidney as indicated by the high uptake values at 2 hours postinjection followed by about a twofold consecutive decrease in 55 CoCl 2 uptake at 24 and 48 hours postinjection (see Table 1 ).
Stability of 55 Co-Chelate Complexes
The stability of radiometal-chelate combinations is crucial when designing new PET imaging probes. Complexes that are not stable in vivo can lead to the radiometal decomplexing from the chelate and accumulating in different organs throughout the body, increasing background signal and dose to nontarget organs. The longer blood clearance associated with the L19K-FDNB peptide that we chose as our model system to investigate 55 Co allows for the potential decomplexation of 55 Co-chelate complexes to be measured at clinically relevant time points to evaluate the in vivo stability of these complexes. It has previously been established that changing the radiometal on peptides can have a drastic effect on the affinity of the peptide to its receptor. 35 Using
55
Co to radiolabel the NO2A-or DO3A-peptides dramatically decreased the affinity for their tumor-associated target, vascular endothelial growth factor (VEGF), 32 as shown by their reduced tumor uptake compared to the 64 Cu-labeled analogue, which was radiolabeled at the same specific activity ( Figure S1 , online version only). Co-DOTA titration curves demonstrating a sevenfold increase in ESA (259 MBq/mmol to 1.96 GBq/mmol) when washing the column with an additional 40 mL 9 M HCl acid versus a 10 mL column wash. Co-DO3A-L19K-FDNB were compared to free 55 CoCl 2 (see Table 1 ). These data show that both NO2A and DO3A chelates radiolabeled with 55 Co exhibit good in vivo stability, as shown by their low uptake in the liver, lung, heart, bone, stomach, and small intestine compared to the high uptake of free 55 CoCl 2 in these organs.
The difference in uptake is most notable in the liver, where the 55 Co-labeled peptides had a sixfold lower uptake than free 55 CoCl 2 at 24 and 48 hours.
Co-labeled peptides had a fourfold lower uptake than free 55 CoCl 2 in the heart at 24 hours and a sevenfold lower uptake at 48 hours. Although the affinity of this particular peptide was negatively affected by radiolabeling with 55 Co, this study shows that DOTA-and NOTA-derived chelates form stable complexes with 55 Co in vivo and may be used to investigate other probes that are insensitive to changes in radiometals.
Discussion
The 58 Ni(p,) 55 Co reaction is an effective route for producing high-specific activity 55 Co. Previously, this method was reported using a copper disk 18 as opposed to gold; however, using copper as the target backing material could have a negative effect on the ESA as copper has a high affinity to both NOTA and DOTA chelators and would compete with Co. This reduction in transchelation for the cobalt complexes is in agreement with the transfer half-life of 800 hours for Co from Co(DOTATOC) in human blood serum measured by Heppeler and colleagues. 7 Additionally, the high positron Zr) leads to similar images with a lower amount of radioactivity administered. One drawback, however, is the higher dose to nontarget tissue from the additional gamma rays present from the decay of 55 Co. Since the affinity of some peptides is dependent on the attached radiometal, it would be interesting to examine this effect on different peptide models. The anti-VEGF peptide used in this work exhibited lower tumor uptake than previously measured with 64 Cu (see Figure S1 , online version only); however, in work done by Heppeler and colleagues, 55 Co-DOTATOC showed higher affinity for the somatostatin type 2 receptor than any other radiometals measured. 7 These different studies imply that 55 Co may also coordinate with the peptide probe concurrently with the chelate to elicit a change in the peptide's affinity for its target. Therefore, determining the structure-activity relationship of these peptide-chelate-metal complexes would be significant for designing superior PET imaging probes. Co-labeled peptides to other radiometals to optimize the best metal-chelate-peptide combination for the application.
Conclusions
